Paeoniflorin Inhibits IgE-mediated Allergic Reactions by Suppressing the Degranulation of Mast Cells Though Binding with FcϵRI Alpha Subunits.

Yongjing Zhang,Shiling Hu,Shuai Ge,Jue Wang,Langchong He
DOI: https://doi.org/10.1016/j.ejphar.2020.173415
IF: 5.195
2020-01-01
European Journal of Pharmacology
Abstract:Paeoniflorin (PF), a monoterpene glycoside isolated from the aqueous extract of the Chinese herb Radix Paeoniae Alba, has been used for treating various inflammatory diseases. In this study, we aimed to investigate the antiallergic activities of PF. The anti-anaphylactic activity of PF was investigated using mast cell (MC) degranulation assay as well as Ca2+ influx in vitro and skin swelling and extravasation assays in vivo. The results showed that PF inhibited MC degranulation (histamine release from 74.5 +/- 4.95 ng/ml to 58.7 +/- 6.06 ng/ml) and Ca2+ influx challenged by DNP-BSA in vitro. In addition, PF reduced the degree of swelling and Evans blue exudation in mice paws. Furthermore, PF dose-dependently reduced serum inflammatory mediator release in mice sensitized with ovalbumin for 48 h by inhibiting MC degranulation. Molecular docking study revealed that PF bound better with the a subunit of FccRI than with the p. subunit. SPR revealed that PF had a strong affinity interaction with FccRI a subunit and the K-D value was (7.08 +/- 0.97) e-6 M. Our findings revealed that PF inhibited anaphylactic responses in vivo and in vitro, and it can be considered a novel FccRI inhibitor for preventing MC-related allergic diseases.
What problem does this paper attempt to address?